ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in San Francisco, CA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis
Dermatitis
Pruritus
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity

Eczema trials near San Francisco, CA, USA:

Locations recently updated

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Enrolling
Atoptic Dermatitis
Drug: EVO756
Drug: Placebo control

Phase 2

Evommune

Fremont, California, United States of America and 16 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Palo Alto, California, United States and 83 other locations

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07275315
Other: Placebo

Phase 2

Pfizer
Pfizer

Lafayette, California, United States of America and 98 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

San Francisco, California, United States and 541 other locations

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Enrolling
Atopic Dermatitis
Drug: Soquelitinib
Drug: Placebo

Phase 1

Corvus Pharmaceuticals
Corvus Pharmaceuticals

Palo Alto, California, United States and 15 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

San Francisco, California, United States and 555 other locations

The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn...

Enrolling
Atopic Dermatitis (AD)
Drug: CGB-500 Ointment with 1% tofacitinib
Drug: Vehicle (placebo)

Phase 2

CAGE Bio

Fremont, California, United States of America and 16 other locations

Locations recently updated

Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib 30mg Dose
Drug: Upadacitinib 15mg Dose

Phase 3

AbbVie
AbbVie

Redwood City, California, United States and 97 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3

AbbVie
AbbVie

Stanford, California, United States and 193 other locations

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Drug: Nemolizumab

Phase 3

Galderma
Galderma

San Francisco, California, United States and 342 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems